A 52-year-old man with chronic kidney disease (eGFR 25 mL/min/1.73 m²) is prescribed two antibiotics: Drug A (90% renal excretion, Vd 0.5 L/kg) and Drug B (10% renal excretion, Vd 3 L/kg). Which parameter best distinguishes the pharmacokinetic impact of renal impairment on these two drugs?

Explanation

## Renal Impairment: Differential Impact on Renally-Dependent vs. Hepatically-Metabolized Drugs ### Pathophysiology of Renal Impairment on Pharmacokinetics When renal function declines, drugs dependent on renal elimination accumulate because clearance is reduced. The impact on half-life depends on the **fraction of total body clearance that is renal**. ### Half-Life Relationship **Key Point:** Half-life is determined by the equation: $$t_{1/2} = \frac{0.693 \times V_d}{CL_{total}}$$ Where $CL_{total} = CL_{renal} + CL_{hepatic} + CL_{other}$ In renal impairment: - **Drug A (90% renal excretion):** Renal clearance drops dramatically → total clearance falls → t_1/2 increases **markedly** - **Drug B (10% renal excretion):** Renal clearance drops, but hepatic clearance remains intact → total clearance minimally affected → t_1/2 increases **minimally** ### Quantitative Comparison | Parameter | Drug A (90% renal) | Drug B (10% renal) | | --- | --- | --- | | **Normal renal function** | CL_total ≈ CL_renal | CL_total ≈ CL_hepatic | | **eGFR 25 (25% of normal)** | CL_total drops ~68% | CL_total drops ~2.5% | | **Half-life change** | 2–3 fold increase | Minimal change | | **Accumulation risk** | **HIGH** | Low | | **Clinical example** | Aminoglycosides, ACE inhibitors | Warfarin, theophylline | **High-Yield:** The **fraction of renal excretion** is the critical determinant of how much half-life changes in renal impairment. A drug with 90% renal excretion will see a much larger relative increase in t_1/2 than a drug with 10% renal excretion. ### Clinical Pearl Aminoglycosides (>90% renal excretion) require aggressive dose reduction or interval extension in CKD to prevent nephrotoxicity and ototoxicity. Warfarin (hepatic metabolism, <5% renal excretion) requires no dose adjustment in renal impairment—only in hepatic disease. ### Why Vd Does Not Change **Warning:** Volume of distribution is a property of drug distribution into tissues and is **independent of renal function**. Vd does not change in renal impairment unless the drug binds to uremic toxins or there is altered protein binding (rare). The half-life change is driven entirely by reduced clearance, not by Vd.